Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan · Delayed Price · Currency is TWD

25.00

-0.05 (-0.20%)

Sep 8, 2026, 11:31 AM CST

Market Cap	6.09B +17.2%
Revenue (ttm)	1.52B +20.1%
Net Income	235.25M +195.1%
EPS	0.98 +174.5%
Shares Out	243.04M
PE Ratio	25.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,306
Open	25.00
Previous Close	25.05
Day's Range	24.80 - 25.10
52-Week Range	22.40 - 29.60
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 20, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2008

Employees 173

Stock Exchange Taipei Exchange

Ticker Symbol 4166

Full Company Profile

Financial Performance

In 2025, Orient Pharma's revenue was 1.40 billion, an increase of 14.52% compared to the previous year's 1.22 billion. Earnings were 208.44 million, an increase of 94.12%.

Financial Statements